3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
41
Carcinoma, Non-Small-Cell Lung
35
Carcinoma, Renal Cell
26
Neoplasm Metastasis
19
Lung Neoplasms
18
Carcinoma, Hepatocellular
15
Squamous Cell Carcinoma of Head and Neck
11
Colorectal Neoplasms
11
Pancreatic Neoplasms
10
Neoplasms
9
Carcinoma, Transitional Cell
9
Multiple Myeloma
8
Urinary Bladder Neoplasms
7
Small Cell Lung Carcinoma
7
Head and Neck Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Hodgkin Disease
6
Advanced Cancer
6
Myelodysplastic Syndromes
5
Hematologic Neoplasms
5
Brain Neoplasms
5
Skin Neoplasms
4
Recurrence
4
Lymphoma
4
Kidney Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Uveal Melanoma
3
Interventions
ofatumumab
3
Vincristine
2
Rituximab
2
Lenalidomide
2
Bortezomib
2
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
nelarabine
1
immunotoxin HA22
1
fludarabine
1
bempegaldesleukin
1
Whole-Body Irradiation
1
Tablets
1
Panobinostat
1
Observation
1
Nivolumab
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Everolimus
1
Etoposide
1
Drug Therapy
1
Dexamethasone
1
DTRMWXHS-12
1
Cytarabine
1
Cyclophosphamide
1
Clofarabine
1
Cladribine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, B-Cell
×
Nivolumab
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts